Why Is Lantern Pharma Stock Soaring Monday?

Lantern Pharma Inc. (NASDAQ: LTRN) shares rose 11.61% to $1.25 in premarket trading on Monday, following a significant drop of over 46% on Friday due to a false report about CEO Panna Sharma's resignation. The company clarified that Sharma remains in his position and the Board of Directors expressed full confidence in his leadership. Additionally, Lantern announced FDA clearance for a Phase 1 pediatric clinical trial of STAR-001, which investors are closely monitoring ahead of the upcoming earnings call scheduled for the fourth quarter of 2025.